Ambrose Health Care Ltd.16 Jul 2025 08:27
Under the option agreement, ValiRx will receive 576,000 shares in Ambrose, with clinical and commercial milestone payments to be made to ValiSeek totalling up to GBP16 million plus royalties.
The initial Β£6 million milestones are payable in cash or the equivalent value in new shares in Ambrose.
~Ambrose will meet all future patent costs and has committed to completing the development and commercialisation of VAL401, ValiRx added."
It looks to me like this is a sell-out to Ambrose, who is now in the driving seat and has the money to take it forward.
Done deal!
Should be some good Val SP gains from here on